New York OKs SEQUENOM's prenatal test

12/28/2007 | Forbes

New York has granted SEQUENOM approval for its noninvasive prenatal test used to detect Rhesus D incompatibility, a fetal disorder that can cause anemia and mental retardation. SEQUENOM's nonexclusive licensee, Lenetix Medical Screening Laboratory, will market the test, which uses SEQureDx technology to draw out fetal nucleic acid material from the mother's blood sample.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC